profile_a69a1ed5bb12afe0ff74e8da56dc3ae0

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland
Professor Paul Van Buynder is a Public Health Physician and the immediate past Chairman of the Australian Immunisation Coalition. He is a Professor in the School of Medicine at Griffith University in Queensland. He has held senior public health positions in a number of Australian states, in two Canadian jurisdictions and at the Centre for Infections in the United Kingdom. He has held personal appointments on sub-committees of National Immunisation Technical Advisory Committees in three continents. He is a reviewer for over 10 journals and has over 60 refereed book chapters and articles.

More from this expert

Videos iconVideos

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Monographs iconMonographs

This article discusses herpes zoster, the condition and its complications as well as the benefits, risks and challenges associated with the herpes zoster vaccine.

Videos iconVideos

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Videos iconVideos

This article discusses herpes zoster, the condition and its complications as well as the benefits, risks and challenges associated with the herpes zoster vaccine.

Monographs iconMonographs

Which booster when? Is bivalent or monovalent better? Plus when non-mRNA boosters are appropriate

Podcasts iconPodcasts

In this Product Explainer, Public Health Physician Prof Paul Van Buynder explains the role of the Bivalent Original/Omicron BA.4-5 pre-filled syringe COVID-19 vaccine and provides an update on the situation in aged care, and how boosters can assist in protecting the community against symptomatic infection and severe disease (5 mins).

Videos iconVideos

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Videos iconVideos